Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Decitabine and Cytarabine in Elderly AML and MDS
NCT02121418Completed
- Sponsor
- University of Washington
- Start
- Jun 2014
- Primary completion
- Feb 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of decitabine in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), Myeloproliferative Neoplasm (MPN) and 1 more, sponsored by University of Washington. Primary endpoints: Overall Survival at 6 months and Complete Response Rate. Started Jun 2014; status: completed.
02
Drugs
decitabine
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)Myeloproliferative Neoplasm (MPN)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on NCT02121418.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02121418.